Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.
Trypanosoma cruzi is a protozoan parasite that causes human Chagas' disease, a leading source of congestive heart failure in Central and South America. CD8+ T cells are critical for control of T. cruzi infection, and CD8+ T cells recognizing the immunodominant trans-sialidase gene-encoded peptide TSKB20 (ANYKFTLV) account for approximately 30% of the total CD8+ T-cell population at the peak of infection in C57BL/6 mice. Type I interferons (IFN-I) are pleiotropic cytokines that play a critical role in both innate and adaptive immunity against a variety of infections, but their induction and their role in infection are dictated by the infectious agent. Because type I IFNs and IFN-responsive genes are evident early after T. cruzi infection of host cells, we examined the influence of IFN-I on the development of CD8+ T-cell responses during this infection. Mice lacking the receptor for IFN-I (IFNARKO) and their wild-type counterparts both developed chronic infections and generated similar frequencies of immunodominant TSKB20- and subdominant TSKB18-specific CD8+ T cells following T. cruzi infection. In contrast, peak TSKB20-specific CD8+ T-cell responses generated during infection with vaccinia virus engineered to express TSKB20 were approximately 2.5-fold lower in IFNARKO mice than B6 mice, although after viral clearance, the frequencies of TSKB20-specific CD8+ T cells stabilized at similar levels. Together, these data suggest that IFN-I induction and biology are dependent upon the microbial context and emphasize the need to investigate various infection models for a full understanding of CD8+ T-cell development.
Martin
Diana L
DL
Department of Cellular Biology and Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia 30502, USA.
Murali-Krishna
Kaja
K
Tarleton
Rick L
RL
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000502:physiology; D014355:Chagas Disease / Q000276:immunology*; D005260:Female; D007111:Immunity, Cellular / Q000276:immunology / Q000502:physiology*; D050835:Interferon Regulatory Factors / Q000235:genetics / Q000276:immunology / Q000502:physiology; D007370:Interferon Type I / Q000276:immunology / Q000502:physiology*; D008213:Lymphocyte Activation / Q000276:immunology / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017471:Receptors, Interferon / Q000276:immunology / Q000502:physiology; D015398:Signal Transduction / Q000276:immunology / Q000502:physiology; D014349:Trypanosoma cruzi / Q000276:immunology*
D050835:Interferon Regulatory Factors; D007370:Interferon Type I; D017471:Receptors, Interferon
Annu Rev Biochem. 1998;67:227-64
9759489
J Immunol. 2009 Feb 15;182(4):2288-96
19201883
J Biol Chem. 2002 Jan 4;277(1):639-44
11668183
Int Immunol. 1996 Jan;8(1):13-22
8671585
J Immunol. 1990 Jan 15;144(2):717-24
2104903
Curr Opin Immunol. 2009 Aug;21(4):385-90
19646853
BMC Genomics. 2009 May 29;10:252
19480704
Nat Immunol. 2003 Oct;4(10):1009-15
14502286
Am J Trop Med Hyg. 1981 Nov;30(6):1189-91
6172988
J Immunol. 2008 Dec 1;181(11):7917-24
19017982
J Exp Med. 2005 Sep 5;202(5):637-50
16129706
Science. 2010 Jan 15;327(5963):291-5
20075244
Nature. 1992 Mar 26;356(6367):338-40
1549177
J Immunol. 2006 Apr 15;176(8):4525-9
16585541
Science. 2005 Jul 15;309(5733):409-15
16020725
Nat Rev Immunol. 2002 Sep;2(9):675-87
12209136
Immunol Rev. 2004 Dec;202:8-32
15546383
J Immunol. 1998 Aug 15;161(4):1947-53
9712065
J Immunol. 2009 Jul 15;183(2):1245-52
19553540
PLoS Pathog. 2006 Aug;2(8):e77
16879036
Curr Opin Immunol. 2002 Aug;14(4):432-6
12088676
J Immunol. 2006 Aug 1;177(3):1746-54
16849484
J Exp Med. 2004 Aug 16;200(4):437-45
15302901
Immunol Rev. 2009 Jan;227(1):75-86
19120477